Dr. Reddy’s Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Financial Results:
Dr Reddy’s Laboratories Ltd reported Revenues for Q1FY25 of ₹7,696.00 Crores up from ₹6,758.00 Crore year on year, a rise of 13.88%.
Total Expenses for Q1FY25 of ₹6,007.00 Crores up from ₹5,086.00 Crores year on year, a rise of 18.11%.
Consolidated Net Profit of ₹1,392.00 Crores down 0.93% from ₹1,405.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹83.46, down 1.07% from ₹84.36 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.